CIC-C1q ELISA | FDA Cleared | Immune complexes


CIC-C1q ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use.

Circulating Immune Complexes

CICs are formed by the interaction of antibodies with immunogenic antigens. Immune complexes with only a slight excess of antibody and antigen are soluble and activate complement. CIC formation may be viewed as a host defence mechanism when directed against foreign antigens. Under normal circumstances CICs are cleared by phagocytosis. If CICs escape phagocytotic clearance they may be deposited in endothelial or vascular structures, thus, provoking an inflammatory response leading to tissue damage. CICs have been associated with an increasing variety of diseases, such as autoimmune, rheumatic, infectious, metabolic, renal, hematological and neoplastic diseases. The CIC-C1q ELISA by BÜHLMANN offers clinicians and researchers a tool that provides useful clinical information regarding immunopathology, prognosis, and follow-up of rheumatic and autoimmune disorders.

Product Information

Method ELISA (96 wells)
Time to result 2 h
Sample type 20 µl serum or plasma (1:50)
Standard range 1-50 µg Eq/ml
Sensitivity < 1 µg Eq/ml
Catalog Number see below
 Status FDA 510(k) cleared, IVD

Download IFU and Catalog Numbers

View the appropriate tab below for your location (US or Canada) and click on the blue underlined catalog number to view the Instructions for Use.

CIC-C1q Informational Flyer


* Multilingual [EN, DE, FR, IT, ES]

CIC-C1q ELISA – EK-CIC-U* (coming soon)

* Multilingual [EN, DE, FR, IT, ES]

US and Canada
Visit our contact page to enter your requests for quotations or to submit an order inquiry.
News and Events
Visit our News page to learn about upcoming events, the latest news about new products, studies and BÜHLMANN in general.